Cargando…
Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor–Resistant Clear Cell Renal Cell Carcinoma()
PURPOSE: Although targeting angiogenesis with tyrosine kinase inhibitors (TKIs) has become standard of care in the treatment of clear cell renal cell carcinoma (RCC), resistance mechanism are not fully understood, and there is a need to develop new therapeutic options overcoming them. METHODS AND MA...
Autores principales: | Jang, Jiryeon, Rath, Oliver, Schueler, Julia, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Choi, Han-Yong, Kwon, Ghee-Young, Park, Woong Yang, Lee, Jeeyun, Park, Se Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358930/ https://www.ncbi.nlm.nih.gov/pubmed/28325666 http://dx.doi.org/10.1016/j.tranon.2017.01.016 |
Ejemplares similares
-
Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023) -
Prognostic Impact of Bone Metastasis on Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated by First Line Tyrosine Kinase Inhibitors: A Propensity-Score Matching Analysis
por: Kang, Minyong, et al.
Publicado: (2020) -
Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma
por: Jee, ByulA, et al.
Publicado: (2022) -
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract
por: Lee, Ji Yun, et al.
Publicado: (2017) -
Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study
por: Hur, Joon Young, et al.
Publicado: (2019)